Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Body Weight Subgroup Analysis of Columba

被引：2

作者：

Mateos, Maria-Victoria ^{[1
]}

Usmani, Saad Z. ^{[2
]}

Grosicki, Sebastian ^{[3
]}

Vorobyev, Vladimir I. ^{[4
]}

Spicka, Ivan ^{[5
]}

Hungria, Vania T. M. ^{[6
]}

Korenkova, Sibirina ^{[7
]}

Bahlis, Nizar ^{[8
]}

Flogegard, Max ^{[9
]}

Blade, Joan ^{[10
]}

Moreau, Philippe ^{[14
]}

Kaiser, Martin F. ^{[11
]}

Iida, Shinsuke ^{[12
]}

Laubach, Jacob P. ^{[13
]}

Masterson, Tara ^{[15
]}

Lantz, Kristen Anne ^{[15
]}

O'Rourke, Lisa ^{[15
]}

Qin, Xiang ^{[16
]}

Parasrampuria, Dolly A. ^{[15
]}

Heuck, Christoph ^{[15
]}

Qi, Ming ^{[15
]}

Nahi, Hareth ^{[17
]}

机构：

[1] Univ Hosp Salamanca, IBSAL, Salamanca, Spain

[2] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

[3] Med Univ Silesian, Sch Publ Hlth, Dept Hematol & Canc Prevent, Katowice, Poland

[4] SP Botkin City Clin Hosp, Moscow, Russia

[5] Gen Fac Hosp, Prague, Czech Republic

[6] Santa Casa Med Sch, Sao Paulo, Brazil

[7] Kiev Ctr Bone Marrow Transplantat, Kiev, Ukraine

[8] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada

[9] Falun Gen Hosp, Dept Internal Med, Falun, Sweden

[10] Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain

[11] Inst Canc Res, Div Mol Pathol, Sutton, Surrey, England

[12] Nagoya City Univ, Grad Sch Med Sci, Dept Hematol & Oncol, Nagoya, Aichi, Japan

[13] Harvard Med Sch, Dana Farber Canc Inst, Dept Hematol & Oncol, Boston, MA 02115 USA

[14] Univ Hosp Nantes, Nantes, France

[15] Janssen Res & Dev LLC, Spring House, PA USA

[16] Janssen Res & Dev LLC, Raritan, NJ USA

[17] Karolinska Inst, Karolinska Univ Hosp, Div Hematol, Dept Med, Huddinge, Sweden

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-122501

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1906

引用

页数：5

共 50 条

[21] Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)
Usmani, Saad Z.
Nahi, Hareth
Mateos, Maria-Victoria
Lokhorst, Henk M.
Chari, Ajai
Kaufman, Jonathan L.
Moreau, Philippe
Oriol, Albert
Plesner, Torben
Benboubker, Lotfi
Hellemans, Peter
Masterson, Tara
Clemens, Pamela L.
Ahmadi, Tahamtan
Liu, Kevin
San-Miguel, Jesus
BLOOD, 2016, 128 (22)
[22] A phase 3 randomized, controlled, open-label study of selinexor, bortezomib, and dexamethasone (SVd) versus bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma (RRMM).
Delimpasi, Sosana
Pour, Ludek
Auner, Holger W.
Dimopoulos, Meletios A.
Rappaport, Alon
Fortin, Lisa
Shah, Jatin J.
Shacham, Sharon
Kauffman, Michael G.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[23] Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)
Usmani, Saad Z.
Quach, Hang
Mateos, Maria-Victoria
Landgren, Ola
Leleu, Xavier
Siegel, David S.
Weisel, Katja
Yang, Hui
Klippel, Zandra K.
Zahlten-Kumeli, Anita
Dimopoulos, Meletios A.
BLOOD, 2019, 134
[24] Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Dimopoulos, Meletios A.
Terpos, Evangelos
Boccadoro, Mario
Delimpasi, Sosana
Beksac, Meral
Katodritou, Eirini
Moreau, Philippe
Baldini, Luca
Symeonidis, Argiris
Bila, Jelena
Oriol, Albert
Mateos, Maria-Victoria
Einsele, Hermann
Orfanidis, Ioannis
Ahmadi, Tahamtan
Ukropec, Jon
Kampfenkel, Tobias
Schecter, Jordan
Qiu, Yanping
Amin, Himal
Vermeulen, Jessica
Carson, Robin
Sonneveld, Pieter
BLOOD, 2020, 136
[25] LINKER-MM3, a phase 3, open-label, randomized study of linvoseltamab versus elotuzumab, pomalidomide, and dexamethasone (EPd) in relapsed/refractory multiple myeloma (RRMM)
Weisel, Katja
Hungria, Vania
Quach, Hang
Yoon, Sung-Soo
Rodriguez-Otero, Paula
Sinha, Arijit
Boyapati, Anita
Lyon, Charlotte
Moore, Vygngley
Inocencio, Tim
Harnett, James
Chi, Lei
Lorenc, Karen Rodriguez
Kroog, Glenn
Voorhees, Peter
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S63 - S64
[26] Oral ixazomib (Ixa), IV daratumumab (Dara), and dexamethasone (dex; IDd) in relapsed/refractory multiple myeloma (RRMM) patients (pts) with 1-3 prior therapies: phase 2 study interim analysis (IA)
Orlowski, Robert
Delimpasi, Sosana
Straub, Jan
Symeonidis, Argiris
Pour, Ludek
Hajek, Roman
Touzeau, Cyrille
Bhanderi, Viralkumar
Pavlicek, Petr
Robak, Pawel
Berdeja, Jesus G.
Matous, Jeffrey V.
Karlin, Lionel
Zweegman, Sonja
Grosicki, Sebastian
Pluta, Andrzej
Kambhampati, Suman
Suryanarayan, Kaveri
Twumasi-Ankrah, Philip
Dash, Ajeeta
Labotka, Richard
Dimopoulos, Meletios-Athanasios
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S154 - S155
[27] Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and 1-3 Prior Therapies: Results of the Final Analysis of a Phase 2 Study
Delimpasi, Sosana
Dimopoulos, Meletios A.
Straub, Jan
Symeonidis, Argiris
Hajek, Roman
Touzeau, Cyrille
Bhanderi, Viralkumar K.
Berdeja, Jesus
Pavlicek, Petr
Matous, Jeffrey, V
Robak, Pawel J.
Suryanarayan, Kaveri
Villareal, Miguel
Cherepanov, Dasha
Srimani, Jaydeep K.
Yao, Huilan
Labotka, Richard
Orlowski, Robert Z.
BLOOD, 2022, 140 : 9995 - 9997
[28] EXCALIBER-RRMM: A phase 3, two-stage study of iberdomide, daratumumab, and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Lonial, Sagar
Quach, Hang
Dimopoulos, Meletios A.
Rodriguez-Otero, Paula
Berdeja, Jesus G.
Richardson, Paul G.
Kyada, Margee
Chu, Shuyu
Chen, Min
Abad, Patricia C.
Morando, Juliane
van de Donk, Niels W. C. J.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[29] An open-label, dose-escalation phase lb study of subcutaneous daratumumab with recombinant human hyaluronidase in patients with relapsed or refractory multiple myeloma (PAVO).
Nahi, Hareth
Hellemans, Peter
Masterson, Tara J.
Clemens, Pamela L.
Ahmadi, Tahamtan
San Miguel, Jesus
Mateos, Maria-Victoria
Usmani, Saad Zafar
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[30] Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma part 2 of the open-label, multicenter, dose-escalation phase Ib study (PAVO)
San-Miguel, Jesus
Usmani, Saad Z.
Mateos, Maria-Victoria
van de Donk, Niels W. C. J.
Kaufman, Jonathan L.
Moreau, Philippe
Oriol, Albert
Plesner, Torben
Benboubker, Lotfi
Liu, Kevin
Hellemans, Peter
Masterson, Tara
Clemens, Pamela L.
Luo, Man
Farnsworth, Andrew
Nahi, Hareth
Chari, Ajai
HAEMATOLOGICA, 2021, 106 (06) : 1725 - 1732

← 1 2 3 4 5 →